Anne Schuchat | Former Principal Deputy Director, CDC; Board Member, Gavi;
Gavi

Anne Schuchat, Former Principal Deputy Director, CDC; Board Member, Gavi;, Gavi

Anne Schuchat, MD served three decades at the Centers for Disease Control and Prevention, including two stints as Acting Director.  She was the first Director of CDC’s National Center for Immunization and Respiratory Diseases and Chief Health Officer during the 2009 influenza pandemic. In the 1990’s, Schuchat spearheaded national guidelines for prevention of group B strep disease in newborns.  Dr. Schuchat retired as a two-star Rear Admiral in the Commissioned Corps of the US Public Health Services.  She is a graduate of Swarthmore College and Dartmouth Medical School and completed an internal medicine residency at NYU’s Manhattan VA Hospital before joining the CDC as an Epidemic Intelligence Service Officer, or disease detective.  She was elected to the National Academy of Medicine and has received numerous awards, including the Fries Prize for Improving Health.  Schuchat serves on the boards of Swarthmore College and GAVI, the Vaccine Alliance.  Her book, The Epi Logs: A CDC Insider’s Story of Saving Lives, Fighting Fear, and Finding Joy (Johns Hopkins University Press) will be released in March 2027. 

Appearances:



Main Conference Day 1 - 9th March @ 15:50

Keynote Panel: The Speed vs. Certainty Paradox: Redefining the Threshold of Evidence for Next-Generation Approvals

The traditional vaccine regulatory paradigm is facing an existential strain. As the threat landscape demands rapid deployment and platform technologies enable unprecedented development velocity, the industry is caught between the rigid certainty of traditional Phase 3 Randomized Controlled Trials (RCTs) and the agile necessity of alternative data pathways. This plenary panel confronts the friction point between classic clinical trial design and emergency health security. Leading regulatory architects, clinical trialists, and public health strategists will debate whether the future of vaccinology lies in demanding flawless, multi-year pre-licensure efficacy baselines, or in pivoting toward expedited approvals backed by aggressive, ultra-responsive adaptive clinical designs and post-market real-world surveillance.

  • Dethroning the RCT: Validating Real-World Evidence (RWE) and Immunogenicity Correlates of Protection for Accelerated Regulatory Tracks
  • The Surveillance Shift: Reallocating Infrastructure Investment from Multi-Year Phase 3 Trials to Real-Time Post-Licensure Safety and Efficacy Tracking
  • Bio-Preparedness vs. Bureaucratic Delay: Navigating the Ethical and Logistical Boundaries of Deploying Vaccines on Provisional Safety Data During Active Outbreaks
  • Harmonizing Global Regulatory Tolerances: Aligning FDA, EMA, and WHO Frameworks on Acceptable Risk Thresholds for Next-Generation Platforms  

    Regulatory Frontline:  MHRA / /WHO/ Health Canada 

    Public Health & Pandemics: CEPI / Gates Foundation

    Industry R&D Pioneers: Sanofi / AstraZeneca / Janssen (former?)

    Medcins Sans Frontiers Representative

    WHO  
last published: 16/Nov/26 13:20 GMT
last published: 16/Nov/26 13:20 GMT

back to speakers